Navigation Links
Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
Date:7/21/2009

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
2. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
3. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
6. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
9. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
10. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
11. AACR Data Highlights InNexus Preclinical Antibody Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 GlaxoSmithKline plc [GSK] (NYSE: ... an exclusive licensing agreement in the United States ... NB-001, a novel, patented compound representing the next ... by NanoBio, NB-001 provides significant antimicrobial activity against ... labialis . ,, Cold sores are a ...
(Date:12/16/2009)... WAYNE, N.J., Dec. 16 MAQUET ... technologies, today announced that it has signed ... Novation, the industry,s leading supply contracting company, ... (EVH) Systems. The VASOVIEW products assist healthcare ... blocked coronary arteries using only small incisions. ...
(Date:12/16/2009)... Inc., a new clinical stage company developing innovative ... on its novel GFPA NMDA receptor modulators, today ... meeting showed that its lead compound GLYX-13 demonstrated ... of the CNS-related side effects seen with other ... also showed that GLYX-13,s antidepressant effects were evident ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6ESCO Announces Major Contract Award for Its Thermoforming Business 54966 1ESCO Announces Major Contract Award for Its Thermoforming Business 54966 2Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2Former GE Executive Joins Lifeclinic International 54960 1Former GE Executive Joins Lifeclinic International 54960 2
... N.J., Jan. 14 Genta,Incorporated (Nasdaq: GNTA ... (FDA) has extended its review of Genta,s appeal ... Application (NDA) that proposed the use,of Genasense(R) (oblimersen ... refractory chronic lymphocytic leukemia. The Company had,previously provided ...
... CVM ) reports financial results for the fiscal ... operating loss for fiscal year 2007 of $9,352,209,versus a ... The loss per,share for fiscal year 2007 was unchanged ... from operating activities used during the year was about,$4,890,100. ...
Other Medicine Technology:FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia 2FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia 3CEL-SCI Corporation Announces 2007 Financial Results 2CEL-SCI Corporation Announces 2007 Financial Results 3
(Date:12/16/2009)... in cardiology. The idea of publishing an ESC Textbook ... cardiovascular imagers, is therefore long awaited. The textbook is ... patient rather than technology-based approach, helping clinicians to explain ... imaging. , The book is divided into sections ... cardiac imaging and its clinical use in all major ...
(Date:12/16/2009)... A diet rich in methionine, an amino acid ... garlic, lentils, onions, yogurt and seeds, can possibly ... to a study by Temple researchers. , The ... Amyloid-β formation and deposition in a mouse model ... Alzheimer Research . , "When methionine reaches too ...
(Date:12/16/2009)... survey of Fortune 1000 employers strongly indicates that wellness programs ... benefits. , ... Minneapolis, MN (PRWEB) ... companies reveals that 78 percent of employers have improved employee ... program. In the survey, conducted by Hallmark Insights, ...
(Date:12/16/2009)... to announce that Chris Wepfer and Jackie Kirby have been ... Traveler magazine’s 2009 Recruiters of the Year Showcase. This is ... and the first for Jackie. , ... ... healthcare staffing agency, is honored to announce that Chris Wepfer ...
(Date:12/16/2009)... Tyco International Ltd. (NYSE: TYC ) ... for election to the Tyco Board of Directors ... 10, 2010. ,, Daniels, 55, is Senior ... of International Business Machines Corporation. In this role, ... business operations consisting of outsourcing services, integrated technology ...
Breaking Medicine News(10 mins):Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Diet high in methionine could increase risk of Alzheimer's 2Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2
... Management Systems,Inc.(R) (HMS) announced today that it was selected ... financial solutions for the hospital and,its two rural health ... for the 26-bed hospital and 126-bed nursing home in ... them closer to an electronic,health record (EHR) for their ...
... 21 Healthcare Executive Colleen A. Cain has been elected ... effective January 1. She replaces Mike Noel who ... committee chair. Cain brings to her new role nearly three ... been a member of the SCAN board of directors since ...
... Med (IM), the leader in,inpatient practice management information ... development aims at aligning software,development directly with client,s ... , Rapid development delivers ... radically reducing the size and duration of iterations ...
... actual discrimination, , , WEDNESDAY, Jan. 21 (HealthDay News) -- ... and are, in various aspects of their life, ... people with schizophrenia in the United States and 26 ... making or keeping friends, 43 percent from family members, ...
... nation,s growing population of breast cancer survivors ages, many ... and heart disease, and they,ll need specialized care to ... therapies they received. They,ll also need screenings and advice ... , But many patients give low marks to the ...
... Mich. A synthetic chemical version of what male ... them into traps and foil the mating process of ... scientists. , Pheromones, chemical scents used to attract a ... MSU professor of fisheries and wildlife, has focused much ...
Other Medicine News:Health News:Yalobusha General Hospital Selects HMS to Provide Information Technology Infrastructure 2Health News:SCAN Health Plan Elects Colleen Cain New Board Chair 2Health News:Ingenious Med Adopts Rapid Software Development, Allowing Customers to Drive Product and Technology 2Health News:Ingenious Med Adopts Rapid Software Development, Allowing Customers to Drive Product and Technology 3Health News:People With Schizophrenia Say Bias Is Part of Their Lives 2Health News:Penn study: Breast cancer survivors call for more 'survivorship care' from primary care physicians 2Health News:Penn study: Breast cancer survivors call for more 'survivorship care' from primary care physicians 3Health News:Chemical come-on successfully lures lovesick lampreys to traps 2
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... Volcano's new VH IVUS technology uses ... simplified interpretation of ultrasound images and ... of each patient's atherosclerotic plaques. The ... component types: fibrous, fibro-fatty, dense calcium, ...
... Internet-based remote monitoring from Medtronic is changing ... follow-up care. Using their Medtronic CareLink Monitor ... conveniently send device information from their home ... web site, clinicians have the ability to ...
... Service provides clinically valuable, device-derived information ... failure to help specialty physicians discern ... are stable or deteriorating. For example, ... a Medtronic InSync Sentry™ CRT-D system ...
Medicine Products: